EP1133492A1 - Procede de fabrication d'hydrochlorure de paroxetine - Google Patents

Procede de fabrication d'hydrochlorure de paroxetine

Info

Publication number
EP1133492A1
EP1133492A1 EP99973025A EP99973025A EP1133492A1 EP 1133492 A1 EP1133492 A1 EP 1133492A1 EP 99973025 A EP99973025 A EP 99973025A EP 99973025 A EP99973025 A EP 99973025A EP 1133492 A1 EP1133492 A1 EP 1133492A1
Authority
EP
European Patent Office
Prior art keywords
paroxetine hydrochloride
propan
solvate
crystalline
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99973025A
Other languages
German (de)
English (en)
Inventor
Andrew Simon Craig
David Alan Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1133492A1 publication Critical patent/EP1133492A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to a process for the preparation of a pharmaceutically active compound and intermediates thereof, and to the use of the active compound in therapy.
  • this invention is concerned with a new process for the preparation of paroxetine chloride propan-2-ol solvate and its use to prepare a crystalline anhydrate form of paroxetine hydrochloride.
  • Paroxetine hydrochloride has been described in the literature as a crystalline hemihydrate (see EP-A-0223403 of Beecham Group) and as various crystalline anhydrate forms (see WO96/24595 of SmithKline Beecham).
  • WO96/24595 describes the preparation of paroxetine hydrochloride propan-2-ol solvate which is a useful intermediate for the preparation of paroxetine hydrochloride anhydrate Form A.
  • paroxetine hydrochloride propan-2-ol solvate When prepared conventionally by crystallisation from anhydrous propan-2-ol, paroxetine hydrochloride propan-2-ol solvate has very poor stirring properties, and is very difficult to isolate, wash, and dry.
  • Lengthy treatment is undesirable for manufacturing because of the costs associated with vessel occupancy, and high temperatures cause degradation and phase transformation in the product.
  • Another undesirable feature of the existing process is the tendency for the product to crystallise in a heavy matted form which is very difficult to stir, transfer, and filter.
  • a glass-lined reactor containing a vigorously stirred solution of 20 kg of paroxetine hydrochloride in 160 litres of propan-2-ol was seeded at 48°C. The entire contents set to a thick crystalline mass, and it was necessary to open the man-way and manually dislodge the contents so that the mixture could be stirred and the product collected. It is therefore evident that the existing process is unsuitable for the large scale manufacture of paroxetine hydrochloride.
  • This invention provides processes for the preparation of paroxetine hydrochloride propan- 2-ol solvate in a form which is more easily desolvated than paroxetine hydrochloride propan-2-ol solvate prepared in a conventional manner, and hence more suitable for commercial manufacturing processes.
  • a process for preparing crystalline paroxetine hydrochloride propan-2-ol solvate which comprises providing a solution of paroxetine hydrochloride in propan-2-ol, adding to the solution a habit modifier compound, and crystallising paroxetine hydrochloride propan-2-ol solvate from the modified solution.
  • Suitable habit modifying compounds are selected from those compounds that are ionic or readily ionisable and are soluble in propan-2-ol.
  • the addition of the indicated habit modifier compound to the solution modifies the habit of the resultant crystals to a form which allows for convenient stirring, filtering and washing on a manufacturing scale, and more effective de-solvation of the crystals.
  • a suitable concentration of paroxetine hydrochloride in propan-2-ol is one part in between 4 and 40 volumes of propan-2-ol, preferably between 8 and 15 volumes, and more preferably between 10 and 14 volumes.
  • the propan-2-ol is anhydrous to suppress formation of paroxetine hydrochloride hemihydrate.
  • Suitable procedures for preparing paroxetine hydrochloride for dissolution in propan-2-ol for use in the process of this invention include those mentioned in US Patents 4,009,196; 4,721,723; 4,902,801; 4,861,893 and 5,039,803.
  • Suitable habit modifiers are carboxylic acids, preferably acetic acid, and amine salts, particularly hydrochloride or acetate salts, for example diethylamine hydrochloride or ammonium acetate.
  • the amount of carboxylic acid habit modifier used is suitably from 1 to 20% of the solvent volume, preferably from 1 to 10%.
  • N suitable amount of amine salt habit modifier is in the range 5-25 mole %, preferably 10- 20 mole %.
  • Crystallisation may be initiated by conventional procedures such as cooling a heated solution, or removing solvent by evaporation or heating. It may be advantageous to add seeds of crystalline paroxetine hydrochloride propan-2-ol solvate prepared by the procedure of this invention or by the procedure of WO 96/24595.
  • the crystalline paroxetine hydrochloride propan-2-ol solvate of modified crystal habit obtainable by the process of this invention is a different crystalline form from the previously known product. This novel product forms another aspect of this invention.
  • Paroxetine hydrochloride propan-2-ol solvate crystals prepared conventionally are large and long, typically with most of the material in the form of crystals in excess of 300 microns in length, with a length-to- width ratio in excess of 40:1, and a volume as measured by for example laser light scattering, of 10,000 cubic microns or more.
  • most of the material is in crystals less than 100 microns long, preferably below 75 microns, and more preferably below 50 microns, and with a length-to- width ratio below 20:1, preferably below 15:1 and more preferably below 10:1, and with a volume below 5,000 cubic microns, preferably below 2,500 cubic microns and more preferably below 1,000 cubic microns.
  • the product of this invention may have either one, two or all three of these desirable characteristics.
  • paroxetine hydrochloride propan-2-ol solvate of modified habit in which the mean distance between crystal facets characterised by the Miller indices (0, 1 , 0) and (0, 1 , 0) in a monoclinic crystal system, P2, space group is minimised, and is preferably below 100 microns.
  • paroxetine hydrochloride propan-2-ol solvate with these characteristics may be processed and desolvated more easily than conventionally produced paroxetine hydrochloride propan-2-ol solvate.
  • the crystallisation process may include if necessary isolating the crystals, optionally washing and drying to remove surface solvent.
  • the crystalline solvate is used as a feed material for desolvation to obtain paroxetine hydrochloride anhydrates, especially the Form A anhydrate.
  • the present invention provides a process for preparing a crystalline anhydrate of paroxetine hydrochloride by heating crystalline propan-2-ol solvate obtainable by the process of this invention to remove bound propan-2-ol.
  • Desolvation is conveniently carried out by heating in an oven, preferably in vacuo, suitably at a temperature of about 60°C.
  • the resultant anhydrate desirably contains less than 3% of propan-2-ol, preferably less than 1%, more preferably less than 0.5%, and most preferably less than 0.1%.
  • the crystalline anhydrate is the Form A anhydrate of paroxetine hydrochloride.
  • the crystalline paroxetine hydrochloride anhydrate obtainable by this invention may be used in therapy in formulations described in EP-A-0223403 or WO 96/00477.
  • Therapeutic uses of the paroxetine hydrochloride anhydrate of this invention include treatment of: alcoholism, anxiety, depression, obsessive compulsive disorder (OCD). panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia. pre-menstrual syndrome (PMS). adolescent depression, trichotillomania. dysthymia, and substance abuse, referred to below as "the disorders”.
  • anhydrate obtainable by the present invention is applied to the treatment of depression, OCD and panic.
  • compositions prepared in accordance with this invention are usually adapted for oral administration, but formulations for dissolution for parental administration are also within the scope of this invention.
  • composition is usually presented as a unit dose composition containing from 1 to
  • unit doses contain 20mg of active ingredient calculated on a free base basis.
  • Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of active ingredient calculated on a free base basis.
  • the unit dose is taken once a day.
  • Preferred unit dosage forms include tablets or capsules, including formulations adapted for controlled or delayed release.
  • compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
  • Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilized in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
  • Specific examples of pharmaceutical compositions include those described EP-B-0223403, and US 4,007,196 in which the anhydrate product of the present invention may be used as the active ingredient.
  • the present invention also provides:
  • compositions for treatment or prophylaxis of the disorders comprising paroxetine hydrochloride anhydrate obtainable by this invention and a pharmaceutically acceptable carrier;
  • paroxetine hydrochloride anhydrate obtainable by this invention to manufacture a medicament for the treatment or prophylaxis of the disorders
  • a method of treating the disorders which comprises administering an effective or prophylactic amount of paroxetine hydrochloride anhydrate obtainable by this invention to a person suffering from one or more of the disorders.
  • the invention is illustrated by the following Examples.
  • drying has been carried out under standardised conditions for the purpose of comparison.
  • Conventionally prepared paroxetine hydrochloride propan-2-ol solvate contains approximately 6% propan- 2-ol under these drying conditions.
  • Paroxetine hydrochloride with lower residual propan- 2-ol can be obtained by increasing the drying time or temperature.
  • Example 1 N solution of paroxetine hydrochloride (10 g) in propan-2-ol (170 ml) was heated at reflux for 1 hour then cooled to 60°C and treated with diethylamine hydrochloride (0.5g). The reaction mixture was slowly cooled to room temperature with stirring. After 3.5 hours the resulting white crystalline solid was filtered, washed with propan-2-ol (40 ml) and dried under vacuum at 60°C for 20 hours to give paroxetine hydrochloride, containing 2.5% propan-2-ol by weight. Heating under vacuum for a further 72 hours caused the propan-2- ol content to fall to 1.8%.
  • paroxetine hydrochloride (10 g) in propan-2-ol (170 ml) was heated at reflux for 1 hour then cooled to 60°C and treated with acetic acid (25 ml). The reaction mixture was slowly cooled to room temperature with stirring. The resulting white crystalline solid was filtered, washed with propan-2-ol (35 ml) and dried in vacuo at 60°C for 20 hours to give paroxetine hydrochloride as acicular crystals, containing 2.8% propan-2-ol by weight. Crystal length by microscopy 40-80 microns.
  • paroxetine hydrochloride 5.0 g
  • propan-2-ol 70 ml
  • acetic acid 5 ml
  • the homogeneous solution was then cooled to room temperature under argon without stirring. Seed crystals of paroxetine hydrochloride propan-2-ol solvate (O.lg) were added and the reaction mixture stirred. Rapid crystallisation ensued to give a thick suspension.
  • the suspension was left for 15 minutes and filtered, washed with propan-2-ol (10 ml) and dried in vacuo for 20 hours at 60°C to give paroxetine hydrochloride containing 2.1 % propan-2-ol by weight.
  • paroxetine hydrochloride anhydrate Form A containing 1.6 % ⁇ ropan-2-ol.
  • paroxetine hydrochloride 4.54 g
  • propan-2-ol 70 ml
  • Ammonium chloride 0.1 g
  • the reaction mixture stirred vigorously and cooled slowly to 45-50°C over 3 hours.
  • the resulting slurry was cooled to ambient temperature, filtered, washed with propan-2-ol (10 ml) and dried in vacuo at 60°C for 20 hours to give paroxetine hydrochloride anhydrate Form A containing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Selon cette invention, un solvate cristallin en propan-2-ol d'hydrochlorure de paroxétine possède un habitus qui est plus facilement désolvaté pour former l'anhydrite; il est obtenu par cristallisation à partir d'une solution d'hydrochlorure de paroxétine dans propan-2-ol à laquelle on avait ajouté un composé modificateur d'habitus. On obtient l'anhydrite de forme A en réchauffant le solvate cristallin à habitus modifié dans un four à vide. Les modificateurs d'habitus les mieux adaptés sont l'acide carboxylique et les sels aminés.
EP99973025A 1998-11-28 1999-11-26 Procede de fabrication d'hydrochlorure de paroxetine Withdrawn EP1133492A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9826176 1998-11-28
GBGB9826176.1A GB9826176D0 (en) 1998-11-28 1998-11-28 Novel process
PCT/GB1999/003968 WO2000032592A1 (fr) 1998-11-28 1999-11-26 Procede de fabrication d'hydrochlorure de paroxetine

Publications (1)

Publication Number Publication Date
EP1133492A1 true EP1133492A1 (fr) 2001-09-19

Family

ID=10843288

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99973025A Withdrawn EP1133492A1 (fr) 1998-11-28 1999-11-26 Procede de fabrication d'hydrochlorure de paroxetine

Country Status (5)

Country Link
EP (1) EP1133492A1 (fr)
JP (1) JP2002531450A (fr)
AU (1) AU1396600A (fr)
GB (1) GB9826176D0 (fr)
WO (1) WO2000032592A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
DE69739561D1 (de) * 1996-06-13 2009-10-15 Sumitomo Chemical Co Piperidin Derivative als Zwischenprodukte zur Herstellung von Paroxetine und Verfahren zu ihrer Herstellung
CA2187128A1 (fr) * 1996-10-04 1997-06-26 K. S. Keshava Murthy Polymorphe nouveau et efficace, a base de chlorhydrate de paroxetine anhydre

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0032592A1 *

Also Published As

Publication number Publication date
JP2002531450A (ja) 2002-09-24
WO2000032592A1 (fr) 2000-06-08
AU1396600A (en) 2000-06-19
GB9826176D0 (en) 1999-01-20

Similar Documents

Publication Publication Date Title
EP0808314B1 (fr) Formes de l'hydrochlorure de paroxetine
CA2782862A1 (fr) Formes polymorphes de chlorhydrate de 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine
EP1137636A1 (fr) Procede de preparation de maleate de paroxetine
EP1137646A1 (fr) Derive paroxetinique
EP1155016A1 (fr) Processus de production de solvate acetonique d'hydrochlorure de paroxetine
WO1999052901A1 (fr) Maleate de paroxetine
EP1133492A1 (fr) Procede de fabrication d'hydrochlorure de paroxetine
EP1135383B1 (fr) Solvates de paroxetine propan-2-ol melanges
WO2000032597A1 (fr) Procede de production d'un solvate propan-2-ol de chlorhydrate de paroxetine
WO2001012623A1 (fr) Procede de preparation d'hydrochlorure de paroxetine anhydre
WO2000032591A1 (fr) Procede de fabrication d'hydrochlorure de paroxetine
SK13622000A3 (sk) Kryštalická forma paroxetínu, farmaceutický prostriedok a použitie
US20020028942A1 (en) Novel process and compound
WO2000078752A1 (fr) Procede de production de chlorhydrate de paroxetine
WO2001046148A1 (fr) Nouveaux procedes
WO2001025230A1 (fr) Procede de preparation de solvate acetonique d'hydrochlorure de paroxetine
WO2000032596A1 (fr) Sels amines de paroxetine
CZ20003343A3 (cs) Krystalická forma paroxetinu
EP1140910A1 (fr) Procede de preparation d'un acetate de paroxetine ou d'analogues de paroxetine
WO2001014369A2 (fr) Nouveau procede
WO2000039090A1 (fr) Procede de preparation d'acetate de paroxetine et de ses analogues
CZ20003722A3 (cs) Maleat paroxetinu
WO2001025231A1 (fr) Preparation d'un solvate cetonique de chlorhydrate de paroxetine
MXPA00009137A (es) Forma cristalina de paroxetina
MXPA00006040A (en) Process for the preparation of paroxetine hydrochloride

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20011119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020403